Should We Consider Patients with Coexistent Hepatitis B or C Infection for Orthotopic Heart Transplantation?

Overview

Journal J Transplant

Publisher Wiley

Specialty General Surgery

Date 2013 Dec 6

PMID 24307939

Authors

Baskar Sekar

Pippa J Newton

Simon G Williams

Steven M Shaw

Affiliations

Soon will be listed here.

Abstract

Heart transplantation (HTX) is the gold standard surgical treatment for patients with advanced heart failure. The prevalence of hepatitis B and hepatitis C infection in HTX recipients is over 10%. Despite its increased prevalence, the long-term outcome in this cohort is still not clear. There is a reluctance to place these patients on transplant waiting list given the increased incidence of viral reactivation and chronic liver disease after transplant. The emergence of new antiviral therapies to treat this cohort seems promising but their long-term outcome is yet to be established. The aim of this paper is to review the literature and explore whether it is justifiable to list advanced heart failure patients with coexistent hepatitis B/C infection for HTX.

References

Roche B, Samuel D . The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011; 31 Suppl 1:104-10. DOI: 10.1111/j.1478-3231.2010.02396.x. View

Reddy K, Everson G . Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. Hepatology. 2013; 58(3):1181-4. DOI: 10.1002/hep.26612. View

Haji S, Avery R, Yamani M, Tuzcu E, Crowe T, Cook D . Donor or recipient hepatitis B seropositivity is associated with allograft vasculopathy. J Heart Lung Transplant. 2006; 25(3):294-7. DOI: 10.1016/j.healun.2005.10.007. View

Chandra M, Khaja M, Hussain M, Poduri C, Farees N, Habeeb M . Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology. 2004; 47(6):374-6. DOI: 10.1159/000080883. View

Valantine H . The role of viruses in cardiac allograft vasculopathy. Am J Transplant. 2004; 4(2):169-77. DOI: 10.1046/j.1600-6143.2003.00316.x. View

Fabrizi F, MARTIN P, Dixit V, Kanwal F, Dulai G . HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5(12):2913-21. DOI: 10.1111/j.1600-6143.2005.01113.x. View

Valantine H . Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation. 2003; 76(6):891-9. DOI: 10.1097/01.TP.0000080981.90718.EB. View

Haji S, Starling R, Avery R, Mawhorter S, Tuzcu E, Schoenhagen P . Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant. 2004; 23(3):277-83. DOI: 10.1016/S1053-2498(03)00148-7. View

Ye L, Li J, Zhang T, Wang X, Wang Y, Zhou Y . Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells. Virus Res. 2012; 168(1-2):33-40. PMC: 3505383. DOI: 10.1016/j.virusres.2012.06.009. View

10.

Hossain M, Coull J, Drusano G, Margolis D . Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. 2002; 55(1):41-52. DOI: 10.1016/s0166-3542(02)00006-2. View

11.

Kim Y, Bae S, Sung Y, Kim T, Jun J, Yoo D . Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol. 2009; 37(2):346-50. DOI: 10.3899/jrheum.090436. View

12.

Knoll G, Tankersley M, Lee J, Julian B, Curtis J . The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997; 29(4):608-14. DOI: 10.1016/s0272-6386(97)90345-0. View

13.

Tinkle C, Haas-Kogan D . Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics. 2012; 6:207-19. PMC: 3421475. DOI: 10.2147/BTT.S23907. View

14.

Stehlik J, Edwards L, Kucheryavaya A, Benden C, Christie J, Dobbels F . The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. J Heart Lung Transplant. 2011; 30(10):1078-94. DOI: 10.1016/j.healun.2011.08.003. View

15.

Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V . Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology. 1988; 94(1):151-6. DOI: 10.1016/0016-5085(88)90623-3. View

16.

Fagiuoli S, Pevere S, Minniti F, Livi U, Caforio A, Naccarato R . Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients. Transplantation. 2003; 75(7):982-6. DOI: 10.1097/01.TP.0000055834.67634.74. View

17.

Gong Z, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E . Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat. 1999; 6(3):229-36. DOI: 10.1046/j.1365-2893.1999.00163.x. View

18.

Inoue K, Yoshiba M . Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant Proc. 2005; 37(2):1233-4. DOI: 10.1016/j.transproceed.2004.11.041. View

19.

Sahi H, Zein N, Mehta A, Blazey H, Meyer K, Budev M . Outcomes after lung transplantation in patients with chronic hepatitis C virus infection. J Heart Lung Transplant. 2007; 26(5):466-71. DOI: 10.1016/j.healun.2007.01.037. View

20.

Dong C, Redenbach D, Wood S, Battistini B, Wilson J, McManus B . The pathogenesis of cardiac allograft vasculopathy. Curr Opin Cardiol. 1996; 11(2):183-90. DOI: 10.1097/00001573-199603000-00012. View